To evaluate the activity of gemcitabine and docetaxel in patients with recurrent 
ovarian cancer.
METHODS: Patients with platinum-resistant disease and prior treatment with 
paclitaxel received treatment with docetaxel on day 1 and gemcitabine on days 1 
and 8, repeated every three weeks.
RESULTS: Twenty patients, with a platinum-free interval of three months, were 
enrolled. Overall response rate was 25%. Treatment was associated with 
significant myelosuppression.
CONCLUSIONS: In chemotherapy-resistant patients, this regimen exhibited 
encouraging activity. Excessive myelosuppression led to early closure. This was 
prevented by administering docetaxel on day 8 (instead of day 1) and 
prophylactic use of G-CSF.